- Utilizing numares’ metabolite constellation revealed a consistent urinary metabolic profile in the first two weeks for living donor kidney recipients, allowing for precise early detection of rejection
- Recipients of deceased donor kidneys display ischemia-driven metabolic changes that temporarily obscure rejection signals
- This pioneering study was headed by researchers from University Hospital Regensburg in partnership with numares Health
REGENSBURG, Germany, March 9, 2026 — numares Health (“numares”), a transformative metabolomics firm leading the way in multidimensional biomarker insights that provide clinical pathways for optimal patient care, today announced the publication of a new analysis in Frontiers in Medicine. This analysis spotlights numares’ urinary metabolite constellation as the first biomarker test to demonstrate reliable diagnostic precision for identifying acute kidney transplant rejection in living donor kidney recipients during the crucial initial 14 days post-transplantation.
The study confirms that while numerous biomarker platforms face challenges in the immediate post-transplant period, the metabolite constellation developed and validated by numares maintains full diagnostic efficacy starting from day one in living donor recipients (AUC 0.72; 95% CI 0.62–0.82).
Acute rejection continues to be a significant hurdle in kidney transplantation, frequently necessitating invasive biopsies for diagnosis. Conventional approaches like serum creatinine monitoring lack both sensitivity and specificity, resulting in overlooked cases or unnecessary medical interventions.
This groundbreaking study, conducted by researchers from University Hospital Regensburg and numares, pinpointed key factors that impact the accuracy of numares’ non-invasive urine test for the early detection of acute kidney allograft rejection, particularly during the immediate post-transplant phase.
Prof. Dr. med. Miriam Banas, from the Department of Nephrology at University Hospital Regensburg, stated: “In contrast to other biomarker methods that can’t be used reliably in the first few days post-transplant, this metabolite constellation preserves its diagnostic power in living donor recipients. This marks a significant step toward ongoing, non-invasive monitoring starting on day one.”
Florian Voss, CEO of numares Health, remarked: “At numares, we employ nuclear magnetic resonance (NMR) spectroscopy to measure multiple biomarkers from a single serum sample. The paper’s results not only validate our technology but also offer new hope for enhancing patient outcomes via personalized post-transplant monitoring.”
numares Health’s urinary test uses NMR metabolomics to aid clinical decision-making regarding kidney transplant rejection. This non-invasive assay analyzes and assesses a previously identified and validated metabolite biomarker constellation, making it ideal for outpatient monitoring to boost patient compliance and reduce the need for invasive, painful, and costly biopsies.
The UMBRELLA study, carried out at the Department of Nephrology of University Hospital Regensburg in Germany, examined 682 urine samples from 109 kidney transplant recipients during the first 14 days after transplantation. It used metabolomic profiling alongside 29 clinical and transplant-related parameters. Ten key confounding factors were identified, such as donor type, ischemia duration, deceased donor status, recipient age, residual urine volume, eGFR, induction therapy, and HLA mismatches.
For more information, please contact:
Optimum Strategic Communications
Nick Bastin | Vici Rabbetts | Vareen Outhonesack | Katherine Bliss
Email: Numares@optimumcomms.com
Tel: +44 (0) 20 4566 8543
About numares Health
numares Health is a leading metabolomics platform that provides multidimensional biomarker insights and clinical pathways to optimize patient care. Its highly automated digital conversion of biochemical pathways uses NMR spectra to measure hundreds of biomarkers simultaneously from a single, minimally processed sample, ensuring precise, consistent, scalable, and streamlined workflows across laboratories, clinical trials/treatments, and regions. Thanks to strong standardization, additional tests can be processed quickly—even from historically collected spectra—speeding up clinical research. These digital biomarkers enable a smooth transition from lab to bedside without needing further chemical intervention, significantly cutting costs while enhancing accuracy and efficiency.
numares Health’s goal is to transform R&D and treatment in the same way genomic analyses revolutionized cancer care—but with a much broader scope covering overlapping disease causes. The company seeks to shift medicine from symptom diagnosis and management to accurately identifying and treating the root causes of diseases.
